I’m not so sure. When pharma companies are flush with cash they tend to get more experimental. Lilly’s gene editing group is one of the few that’s doing well (last I heard anyway) and they recently acquired Verve. I can’t imagine that would happen without GLP-1 profits bankrolling everything. Rare disease is effectively charity and the money has to come from somewhere.